Rett综合征与MECP2重复综合征的理解进展:未来治疗前景
本文综述了MECP2基因功能缺失导致的Rett综合征和MECP2基因重复导致的MECP2重复综合征这两种严重神经发育障碍。研究通过MeCP2在神经元基因表达调控机制、动物模型及临床表型观察,积累了针对病理生理而非仅症状的治疗思路证据。未来十年左右,反义寡核苷酸、深部脑刺激和基因治疗可能进入临床。
要点
- MECP2功能缺失致Rett综合征,MECP2重复致MECP2重复综合征。
- MeCP2调控神经元基因表达机制及动物模型研究已阐明部分问题。
- 治疗策略可靶向MECP2障碍的病理生理,而非仅针对症状。
核心结论
- 已有足够证据提示可针对MECP2障碍的病理生理而非仅症状来开发疗法。
研究设计与样本
- 综述了MeCP2在神经元基因表达调控机制、携带不同致病突变的动物模型及临床表型观察的研究进展。
主要发现
- MeCP2在神经元基因表达调控机制、动物模型及临床表型观察的研究已澄清一些问题但也提出新问题。
临床怎么用
- 可能将反义寡核苷酸、深部脑刺激和基因治疗作为未来十年左右进入临床的候选疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The X-linked gene encoding MECP2 is involved in two severe and complex neurodevelopmental disorders. Loss of function of the MeCP2 protein underlies Rett syndrome, whereas duplications of the MECP2 locus cause MECP2 duplication syndrome. Research on the mechanisms by which MeCP2 exerts effects on gene expression in neurons, studies of animal models bearing different disease-causing mutations, and more in-depth observations of clinical presentations have clarified some issues even as they have raised further questions. Yet there is enough evidence so far to suggest possible approaches to therapy for these two diseases that could go beyond attempting to address specific signs and symptoms (of which there are many) and instead target the pathophysiology underlying MECP2 disorders. Further work could bring antisense oligonucleotides, deep brain stimulation, and gene therapy into the clinic within the next decade or so.
引用
- Sandweiss AJ, Brandt VL, Zoghbi HY, et al. Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies. Lancet Neurol. 2020. PMID: 32702338. doi:10.1016/S1474-4422(20)30217-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。